Resof Total tablets It is the first pan-genotype (for all genotypes, from 1 to 6) combined drug for the treatment of chronic viral hepatitis C with a regimen of 1 tablet a day. The formulation includes a nucleotide analogue of the inhibitor of the polymerase cofosbuvir at a dosage of 400 mg and the pentgenotype NS5A inhibitor veltapasvir in a dosage of 100 mg. The recommended duration of the EPCLUSA course is 12 weeks without ribavirin for patients without cirrhosis or with compensated liver cirrhosis (Child-Pugh A). The drug is also approved for use in a course of 12 weeks in combination with ribavirin for patients with decompensated liver cirrhosis (Child-Pugh B or C).